Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125191 | 0.86 | ELANE (0.46) | HTR7HTR2BELANELMNAKMT2A | |
| SCHEMBL21266322 | 0.85 | HSD17B10 (0.35) | HTR7HTR2BELANEGAAKMT2A | |
| SCHEMBL2606426 | 0.84 | LMNA (0.36) | HTR7HTR2BELANELMNAGAA | |
| SCHEMBL23082336 | 0.82 | MAPT (0.33) | HTR7HTR2BELANEKMT2A | |
| SCHEMBL2604688 | 0.79 | ELANE (0.39) | ELANELMNAGAAKMT2AATM | |
| SCHEMBL21266153 | 0.78 | KMT2A (0.37) | LMNAGAAKMT2A | |
| SCHEMBL6536369 | 0.78 | LMNA (0.47) | ELANELMNAGAAKMT2AOPRM1 | |
| SCHEMBL22596883 | 0.78 | ALDH1A1 (0.31) | LMNA | |
| SCHEMBL2122679 | 0.78 | THRB (0.45) | HTR7HTR2BLMNAKMT2AOPRM1 | |
| SCHEMBL14088598 | 0.77 | HTT (0.47) | LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | KLK3, PDE7A, FZD7 | HTR7 142/4885HTR2B 1352/4885ELANE 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.